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httpProspective, randomized, multi-institutional clinical
trial of a silver alginate dressing to reduce lower
extremity vascular surgery wound complications
C. Keith Ozaki, MD,a Allen D. Hamdan, MD,b Neal R. Barshes, MD, MPH,c Mark Wyers, MD,b
Nathanael D. Hevelone, MPH,a Michael Belkin, MD,a and Louis L. Nguyen, MD, MBA, MPH,a Boston,
Mass; and Houston, Tex
Objective: Wound complications negatively affect outcomes of lower extremity arterial reconstruction. By way of an
investigator initiated clinical trial, we tested the hypothesis that a silver-eluting alginate topical surgical dressing would
lower wound complication rates in patients undergoing open arterial procedures in the lower extremity.
Methods: The study block-randomized 500 patients at three institutions to standard gauze or silver alginate dressings
placed over incisions after leg arterial surgery. This original operating room dressing remained until gross soiling, clinical
need to remove, or postoperative day 3, whichever was ﬁrst. Subsequent care was at the provider’s discretion. The primary
end point was 30-day wound complication incidence generally based on National Surgical Quality Improvement Program
guidelines. Demographic, clinical, quality of life, and economic end points were also collected. Wound closure was at the
surgeon’s discretion.
Results: Participants (72%male)were84%white, 45%werediabetic, 41%had critical limb ischemia, and32%hadclaudication
(with aneurysm, bypass revision, other). Theoverall 30-daywound complication incidencewas30%,with superﬁcial surgical
site infection as the most common. In intent-to-treat analysis, silver alginate had no effect on wound complications.
Multivariable analysis showed thatCoumadin (Bristol-Myers Squibb,Princeton,NJ; odds ratio [OR], 1.72; 95%conﬁdence
interval [CI], 1.03-2.87; P [ .03), higher body mass index (OR, 1.05; 95% CI, 1.01-1.09; P [ .01), and the use of no
conduit/material (OR, 0.12; 95% CI, 0.82-3.59; P < .001) were independently associated with wound complications.
Conclusions: The incidence of wound complications remains high in contemporary open lower extremity arterial
surgery. Under the study conditions, a silver-eluting alginate dressing showed no effect on the incidence of wound
complications. (J Vasc Surg 2015;61:419-27.)2,3Open vascular surgical procedures in the lower extrem-
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Disease Control and Prevention Guideline for Prevention
of Surgical Site Infection recommends the use of a sterile
dressing to protect closed incisions for 24 to 48 hour post-
operatively.4 However, no evidence-based recommenda-
tions are made with regards to dressing types for use in
postoperative incision care. Even more recent reviews fail
to provide detailed guidance.5
A plethora of wound dressings are available in the mar-
ket, with silver-based dressings among these recent innova-
tions. Topical silver treatment is an effective bactericidal
agent that does not induce bacterial resistance when
used in therapeutic levels.6 Acticoat Absorbent (Smith &
Nephew PLC, London, United Kingdom) is an antimicro-
bial barrier dressing coated with nanocrystalline silver that
delivers a controlled, sustained (up to 3 days) dose of silver
ions, according to the manufacturer. This alginate also
dressing absorbs moisture (minimizing wound maceration)
and is safe and effective against a broad range of microor-
ganisms. Acticoat is indicated for surgical wounds, chronic
wounds, and burn wounds; however, data are lacking
regarding in its potential role in postoperative surgical inci-
sion wound infection prophylaxis.
We previously reported a nonconcurrent, single-
institution study of patients who received a conventional
nonsilver-containing dressing vs Acticoat as the419
Fig. Enrollment, randomization, treatment, and follow up data. More than 99% of patients received their assigned
dressing.
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revascularizations.7 The wound complication rate was
14% (17 of 118) for the control group and 5% (7 of
130) for the treatment group. These ﬁndings suggested
possible effectiveness for an Acticoat-based dressing sys-
tem. On the basis of these data, we moved forward with
a prospective, multi-institutional, randomized clinical trial
to test the hypothesis that immediate application of Acti-
coat as a postoperative dressing would reduce closed inci-
sional wound complications in patients undergoing lower
extremity revascularizations involving infrainguinal skin in-
cisions compared with standard nonsilver-eluting dressing
material.
METHODS
Appropriate institutional approvals at two academic
tertiary care medical centers and one Department of Veter-
ans Affairs medical center were secured. Participation was
offered to consecutive eligible patients starting in October
2010 and concluding in September 2013, and patients pro-
vided written, informed consent. Inclusion criterion
included adults (capable of informed consent) undergoing
an open (an incision below the inguinal ligament),
nonemergency surgical procedure for peripheral vascular
disease involving arteries or bypass grafts, with the anticipa-
tion that all incisions would be closed. Open cases com-
bined with endovascular approaches were acceptable. The
study excluded patients aged <18 years old, those with a
known allergy to silver or alginate, participation in another
interventional clinical trial, or prior participation in the cur-
rent study.
Patients were randomized in the operating room by
block design after wound closure was completed but before
any dressing was applied. The wound-closure techniquewas at the discretion of the surgeon. Cyanoacrylate tissue
adhesives (eg, Dermabond; Ethicon, Somerville, NJ)
were considered as dressings and were not permitted.
The ﬁnal operating room dressing (silver vs standard) was
secured on the wound according to surgeon preference.
The practice requested of the provider teams at a kick-off
presentation and subsequent ongoing education was to
leave the original operating room dressing in place until
gross soiling impaired standard wound hygiene, there was
a clinical need to remove the dressing, or postoperative
day 3, whichever came ﬁrst. Subsequent dressings and
wound care was at the discretion of providers.
Incision outcome at 30-days served as the primary end
point. Wounds underwent visual wound checks at least at
w2 and 4 weeks by the primary surgical team. Wounds
(all infrainguinal incisions, including arterial exposure,
vein harvest, etc.) were graded (Appendix I, online
only) as having no wound complication, superﬁcial surgi-
cal site infection (SSI), deep SSI, dehiscence (wound sep-
aration that required local wound care), or other (seroma,
lymphocele, hematoma, etc). Although categories were
based on the widely accepted National Surgical Quality
Improvement Program deﬁnitions,8 more liberal cate-
gories were included to capture sometimes murky “dehis-
cence” and “other” events that affect patient-centric and
health care economic outcomes. A host of demographic,
clinical, quality of life, and economic data were collected
prospectively as patients were enrolled (Appendix II,
online only).
The planned study enrollment was based on prior sam-
ple size calculations. We estimated an end point event rate
of at least 25%2,3 and set a detection threshold of a 10% ab-
solute (40% relative) wound complication rate reduction.7
Thus, with a power of 0.8, a of .05, control event rate of
Table I. Demographics and medical history
Variables Total (N ¼ 500)
Intent to treat
P valueSilver (n ¼ 250) Conventional (n ¼ 250)
Age, mean (SD), years 67.6 (10.5) 68.4 (10.2) 66.9 (10.6) .12
Race, No. (%)
White 418 (83.6) 213 (85.2) 205 (82.0) .18
Black 62 (12.4) 29 (11.6) 33 (13.2)
Hispanic 17 (3.4) 5 (2.0) 12 (4.8)
Asian/Paciﬁc Islander 2 (0.4) 2 (0.8) 0 (0)
Native American 1 (0.2) 1 (0.4) 0 (0)
Sex, No. (%)
Female 139 (27.8) 69 (27.6) 70 (28.0) .92
Male 361 (72.2) 181 (72.4) 180 (72.0)
Height, mean (SD) inches 67.7 (3.8) 67.7 (3.9) 67.7 (3.7) .95
Weight, mean (SD) pounds 180.5 (43.7) 180.5 (44.1) 180.6 (43.4) .98
BMI, mean (SD) kg/m2 27.6 (5.7) 27.6 (5.6) 27.6 (5.9) .90
Prior CAD intervention (PTCA/CABG), No. (%) 165 (33.0) 83 (33.2) 82 (32.8) .92
DM, No. (%)
None 276 (55.2) 143 (57.2) 133 (53.2) .67
IDDM 113 (22.6) 54 (21.6) 59 (23.6)
NIDMM 111 (22.2) 53 (21.2) 58 (23.2)
Renal function, No. (%)
Normal 464 (92.8) 229 (91.6) 235 (94.0) .32
Renal insufﬁciency (creatinine >2 mg/dL) 23 (4.6) 15 (6.0) 8 (3.2)
Dialysis 13 (2.6) 6 (2.4) 7 (2.8)
History of
Hypertension, No. (%) 446 (89.2) 224 (89.6) 222 (88.8) .77
Myocardial infarction, No. (%) 115 (23.0) 58 (23.2) 57 (22.8) .92
Stroke, No. (%) 54 (10.8) 25 (10.0) 29 (11.6) .56
Laboratory values, mean (SD)
WBC, 109/L 8 (2.6) 8 (2.6) 8 (2.6) .93
Hematocrit, % 42.8 (106.2) 37.6 (6.0) 47.9 (150.0) .28
Platelets 109/L 246.2 (101.8) 252.6 (117.8) 239.9 (82.6) .16
Glucose, mg/dL 122.4 (46.2) 122.9 (45.4) 121.8 (47.0) .78
Creatinine, mg/dL 1.2 (1.0) 1.2 (1.2) 1.2 (0.8) .44
Albumin, g/dL 4.3 (4.9) 4.5 (7.0) 4.0 (0.5) .42
Hemoglobin A1c, % 8.7 (21.7) 10.5 (31.3) 7.1 (1.6) .32
C-reactive protein, mg/L 32.5 (44.5) 27.2 (41.2) 44.6 (52.5) .40
Medications, No. (%)
Aspirin 423 (84.9) 211 (84.4) 212 (85.5) .74
ACE inhibitor 256 (51.4) 128 (51.2) 128 (51.6) .93
Antibiotics 84 (16.9) 37 (14.8) 47 (19.0) .22
b-Blocker 330 (66.3) 173 (69.2) 157 (63.3) .16
Coumadina 88 (17.7) 43 (17.2) 45 (18.2) .78
Low-molecular-weight heparin 19 (3.8) 10 (4.0) 9 (3.6) .83
Clopidogrel 120 (24.1) 60 (24.0) 60 (24.2) .96
Statin 408 (81.9) 201 (80.4) 207 (83.5) .37
Steroids 30 (6.0) 12 (4.8) 18 (7.3) .25
ACE, Angiotensin converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; DM, diabetes mellitus;
IDDM, insulin-dependent diabetes mellitus; NIDMM, noninsulin-dependent diabetes mellitus; PTCA, percutaneous coronary angioplasty; SD, standard
deviation; WBC, white blood cells.
aBristol-Myers Squibb, Princeton, NJ.
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a total study sample size of 250 per group (500 total) was
planned.
Clinical data were collected using the Research Elec-
tronic Data Capture (REDCap)9 system, a secure, Web-
based application for research. All data were analyzed as
intention-to-treat. Continuous variables were analyzed
using the Student t-test or analysis of variance, as appro-
priate, and categoric data were analyzed using c2 tests.
Multivariable analysis was performedusing logistic regressionmodels with backwards elimination using inclusion
threshold of P ¼ .20. An a ¼ .05, corresponding to
P ¼ .05, and 95% conﬁdence intervals (CIs) were used
as the criteria for statistical signiﬁcance. Statistical analysis
was performed using SAS 9.3 software (SAS Institute
Inc, Cary, NC).
RESULTS
The 500 study participants were enrolled on timetable.
The Veterans Administration site was added in May 2012
Table II. Operative indications and characteristics
Variables Total (N ¼ 500)
Intent to treat
P valueSilver (n ¼ 250) Conventional (n ¼ 250)
Indication, No. (%)
Claudication 158 (31.6) 76 (30.4) 82 (32.8) .71
Critical limb ischemia 207 (41.4) 100 (40.0) 107 (42.8)
Rest pain 71 (14.2) 37 (14.8) 34 (13.6)
Tissue loss 136 (27.2) 63 (25.2) 73 (29.2)
Abdominal aneurysm 56 (11.2) 32 (12.8) 24 (9.6)
Peripheral aneurysm 22 (4.4) 10 (4.0) 12 (4.8)
Bypass revision 32 (6.4) 17 (6.8) 15 (6.0)
Other 25 (5.0) 15 (6.0) 10 (4.0)
Procedure side, No. (%)
Left 179 (35.8) 96 (38.4) 83 (33.2) .38
Right 196 (39.2) 97 (38.8) 99 (39.6)
Bilateral 125 (25.0) 57 (22.8) 68 (27.2)
Surgical site, No. (%)
Suprainguinal inﬂow to femoral 47 (9.5) 21 (8.5) 26 (10.5) .96
Femorofemoral 17 (3.4) 7 (2.8) 10 (4.0)
Groin only 159 (32.1) 79 (31.9) 80 (32.3)
Femoral above-knee popliteal 55 (11.1) 31 (12.5) 24 (9.7)
Femoral below-knee popliteal 56 (11.3) 26 (10.5) 30 (12.1)
Femoral tibial/pedal 102 (20.6) 54 (21.8) 48 (19.4)
Popliteal tibial/pedal 26 (5.2) 13 (5.2) 13 (5.2)
Tibial/pedal 2 (0.4) 1 (0.4) 1 (0.4)
Other 32 (6.5) 16 (6.5) 16 (6.5)
Conduit, No. (%)
Autogenous 213 (42.6) 104 (41.6) 109 (43.6) .23
Nonautogenous 231 (46.2) 112 (44.8) 119 (47.6)
No conduit 56 (11.2) 34 (13.6) 22 (8.8)
Clean classiﬁcation, No. (%) 463 (92.8) 228 (91.6) 235 (94.0) .29
Sterile preparation solution, No. (%)
Betadine based 45 (9.0) 21 (8.4) 24 (9.6) .66
Chlorhexidine based 437 (87.6) 222 (88.8) 215 (86.4)
Other 17 (3.4) 7 (2.8) 10 (4.0)
Estimated blood loss, mean (SD), mL 375.5 (429.5) 354.5 (383.2) 396.6 (471.1) .27
Operative time, mean (SD), minutes 263 (104) 253 (97) 273 (110) .03
Incision length, mean (SD), cm 32.2 (23.2) 31.6 (22.3) 32.8 (24.2) .53
SD, Standard deviation.
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enrollment data. There were no dressing-speciﬁc com-
plications, and >99% of patients received their assigned
dressing. Two patients crossed over from standard gauze
to the silver-eluting alginate when the operating room
team misunderstood the assigned randomization, and one
crossed over when a participating investigator felt that the
assigned dressing disadvantaged the patient’s recovery
from the operation.
The cohort represented both sexes (male-to-female ra-
tio: 2.6:1), displayed some racial diversity (w84% white),
and held medical comorbidities typical of contemporary
vascular surgery practices (Table I). Indications for opera-
tion were primarily related to arterial occlusive disease,
with critical limb ischemia the most common (Table II).
Groin exposures were required in 56 patients for sup-
rainguinal endovascular aneurysm repair. Reconstruction
material was used in 440 patients (88.8%), including autog-
enous in 211 (42.2%), prosthetic, including heterograft,
in 220 (44.0%), composite in 6 (1.2%), and homografts
in 7 (1.4%). Most of the cases were clean cases, andchlorhexidine-based preparation solutions were used in
almost nine of ten patients. The incision length at risk for
the primary outcome averaged 32.2 6 23.2 (standard de-
viation) cm. Of the factors examined, only operative time
differed signiﬁcantly between randomization groups, at
273 minutes with conventional gauze vs 253 minutes
with silver alginate (P ¼ .028).
On the basis of an intention-to-treat analysis, the pri-
mary end point event rate was statistically identical between
groups (P ¼ .87; Table III). Analysis by actual dressing
type did not change this ﬁnding. Restriction of the compli-
cations to those that were infections also failed to demon-
strate any effect of dressing type (P ¼ .639).
Because groin exposure for endovascular aneurysm
repair (EVAR) stands as a distinct entity from the other
procedures for infrainguinal vascular disease, we analyzed
these patients separately (Table IV). Wound problems
developed in 33% of non-EVAR cases, whereas the compli-
cation rate was 6.6% for the EVAR patients. Again, analyses
of the dressing type in the non-EVAR and EVAR cohorts
showed no effect.
Table III. Wound complications
Variables
Overall (N ¼ 500),
No. (%)
Intent to treat
P valueSilver (n ¼ 250), No. (%) Conventional (n ¼ 250), No. (%)
Patients with follow-up 493 247 246
Worst complication
No wound complication 352 (70.4) 175 (70.0) 177 (70.8) .84
Other 25 (5.0) 10 (4.0) 15 (6.0)
Wound dehiscence 43 (8.6) 23 (9.2) 20 (8.0)
Superﬁcial SSI 61 (12.2) 32 (12.8) 29 (11.6)
Deep SSI 19 (3.8) 10 (4.0) 9 (3.6)
Any SSI (superﬁcial or deep) 80 (16.2) 42 (17.0) 38 (15.5) .64
Any wound complication 148 (30.0) 75 (30.4) 73 (29.7) .87
SSI, Surgical site infection.
Table IV. Wound complications by procedure
Variables Overall, No. (%)
Intent to treat
P valueSilver, No. (%) Conventional, No. (%)
Revascularizations (non-EVAR)
No. 438 215 223
No. used (have follow-up data) 432 212 220
Worst complication:
No wound complication 294 (67.1) 143 (66.5) 151 (67.7) .84
Other 23 (5.3) 9 (4.2) 14 (6.3)
Wound dehiscence 42 (9.6) 22 (10.2) 20 (9.0)
Superﬁcial SSI 61 (13.9) 32 (14.9) 29 (13.0)
Deep SSI 18 (4.1) 9 (4.2) 9 (4.0)
Any SSI (superﬁcial or deep) 79 (18.3) 41 (19.3) 38 (17.3) .58
Any wound complication 144 (33.3) 72 (34.0) 72 (32.7) .79
EVAR
No. 62 35 27
No. used (have follow-up data) 61 35 26
No wound complication 58 (93.6) 32 (91.4) 26 (96.3) .66
Other 2 (3.2) 1 (2.9) 1 (3.7)
Wound dehiscence 1 (1.6) 1 (2.9) 0 (0)
Superﬁcial SSI 0 (0) 0 (0) 0 (0)
Deep SSI 1 (1.6) 1 (2.9) 0 (0)
Any SSI (superﬁcial or deep) 1 (1.6) 1 (2.9) 0 (0) .38
Any wound complication 4 (6.6) 3 (8.6) 1 (3.9) .46
EVAR, Endovascular aneurysm repair; SSI, surgical site infection.
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wound complication rate for this subset was 21.9% in the
setting of standard gauze and 20.2% for patients who
received the silver alginate dressing (P ¼ .75 by c2).
In secondary analyses, we noted a trend based on initial
case wound classiﬁcation. Complications occurred in seven
of 21 nonclean silver dressing patients (clean/contami-
nated, contaminated, or dirty/infected; 33.3%) and in 10
of 15 (66.6%) in the setting of a standard gauze dressing
(P ¼ .048 by c2). Note that there is some uncertainty in
the quality of these data because 25 patients were classiﬁed
as “clean/contaminated,” which typically indicates entry of
a hollow viscus or clear break in sterile technique.
Multivariable analysis (Table V) showed that preopera-
tive Coumadin (Bristol-Myers Squibb, Princeton, NJ) use
(odds ratio [OR], 1.72, 95% CI, 1.03-2.87; P ¼ .03),
higher body mass index (BMI; OR, 1.05; 95% CI,1.01-1.09; P ¼ .01), and the use of no conduit/material
(OR, 0.12; 95% CI, 0.82-3.59; P < .001) were indepen-
dently associated with wound complications.
DISCUSSION
The current study ﬁnds continued high wound compli-
cation rates for open vascular surgery in the lower extrem-
ity. A silver-eluting alginate dressing displayed no apparent
effect on these complication rates.
One of the most common postoperative complications
of surgical procedures remains SSI, which causes signiﬁcant
morbidity and health care costs among hospitalized pa-
tients.10,11 Surgical wounds for lower extremity revascular-
ization are particularly prone to infection and dehiscence,
with rates in some series as high as 44%.2 One attempt at
mitigating this problem is the use of less invasive ap-
proaches, including endoscopic vein harvest.12 Because
Table V. Wound complications by patient characteristics
Variables
Bivariate Multivariable
OR (95% CI) P valuea OR (95% CI) P valuea
Silver dressing 1.03 (0.70-1.52) .87 0.91 (0.61-1.37) .65
Age 0.99 (0.97-1.01) .14
Race
White Reference
Black 0.93 (0.51-1.66) .80
Other 0.57 (0.19-1.73) .32
Sex
Female Reference
Male 0.71 (0.47-1.09) .12
BMI 1.04 (1.01-1.08) .02 1.05 (1.01-1.09) .01
Prior CAD intervention (PTCA/CABG) 1.22 (0.82-1.84) .33
Abnormal renal function 0.76 (0.35-1.66) .50
History of
Diabetes (IDDM or NIDMM) 1.03 (0.70-1.51) .90
Hypertension 0.99 (0.53-1.84) .98
Myocardial infarction 1.18 (0.75-1.85) .47
Stroke 0.84 (0.44-1.61) .61
Indication
Claudication Reference
Critical limb ischemia 0.75 (0.49-1.17) .20
Abdominal aortic aneurysm 0.13 (0.04-0.36) <.001
Peripheral aneurysm 0.60 (0.22-1.61) .31
Bypass revision 0.31 (0.11-0.84) .02
Other 0.62 (0.24-1.57) .31
Revascularization Reference
EVAR 0.14 (0.05-0.39) <.001
Surgical site
Groin only Reference
Groin and leg mixed 2.42 (1.59-3.67) <.0001
All wounds lower than groin 1.45 (0.69-3.04) .33
Conduit
Autogenous Reference Reference
Nonautogenous 0.58 (0.39-0.87) .01 0.82 (0.49-1.39) .47
No conduit 0.09 (0.03-0.29) <.0001 0.12 (0.03-0.41) <.001
Nonclean classiﬁcation 2.22 (1.12-4.40) .02 1.72 (0.82-3.59) .15
Sterile preparation solution
Betadine based Reference
Chlorhexidine based 1.37 (0.67-2.79) .39
Other 1.29 (0.37-4.47) .69
Estimated blood loss 1.00 (1.00-1.00) .17
Operative time 1.00 (1.00-1.00) .01
Total incision length 1.02 (1.01-1.03) <.0001 1.01 (1.00-1.02) .16
Laboratory values
WBC 1.02 (0.94-1.10) .65
Hematocrit 1.00 (1.0-1.01) .42
Platelets 1.00 (1.00-1.00) .09
Glucose 1.0 (0.99-1.00) .43
Creatinine 0.87 (0.68-1.10) .25
Albumin 0.81 (0.51-1.30) .39
Hemoglobin A1c 0.99 (0.95-1.04) .66
C-reactive protein 1.00 (0.98-1.02) 1.00
Medication use
Aspirin 1.30 (0.74-2.27) .36
ACE inhibitors 1.10 (0.75-1.62) .63
Antibiotics 1.22 (0.73-2.03) .44
b-Blockers 0.97 (0.65-1.46) .89
Coumadinb 1.71 (1.05-2.77) .03 1.72 (1.03-2.88) .04
Low-molecular-weight heparin 1.37 (0.53-3.55) .52
Clopidogrel 1.32 (0.85-2.06) .21
Statins 1.21 (0.72-2.02) .47
Steroids 0.99 (0.44-2.22) .99
ACE, Angiotensin-converting enzyme; BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CI, conﬁdence interval;
EVAR, endovascular aneurysm repair; IDDM, insulin-dependent diabetes mellitus; NIDMM, noninsulin-dependent diabetes mellitus; OR, odds ratio; PTCA,
percutaneous coronary angioplasty; WBC, white blood cell.
aP < .05 indicates statistical signiﬁcance.
bBristol-Myers Squibb, Princeton, NJ.
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dressings are a potential avenue for subsequent underlying
devitalized tissue contamination and infection in these
frequently immunologically incompetent patients, we theo-
rized that lowering bacterial counts overlying the incisions
early postoperatively might have a durable beneﬁcial effect
on postoperative wound problems.
Silver pharmacologic compounds and silver-eluting
biomaterials have shown efﬁcacy in a variety of clinical ap-
plications for infection prophylaxis and therapy,6 largely in
the chronic wound and burn settings. For closed postoper-
ative surgical incisions, a trial in 110 elective colorectal sur-
gery patients showed safety and efﬁcacy in preventing
SSI (13% with silver nylon dressing vs 33% with standard
gauze).13 However, another trial in colorectal patients
showed only a statistically insigniﬁcant trend in SSI.14
In the lower extremity, silver hydrogel sheet dressings (pe-
troleum-based control dressing) on foot and ankle surgical
incisions displayed fewer infections and incisional complica-
tions, although the power of the report was low.15
In a study reported in 2007,we observed fewer lower ex-
tremity revascularization wound infections associated with
the use of a silver-eluting dressing.7 In that report and in
the current trial, the surgeons and other providers found
the dressing regimen was easy to apply and care for postop-
eratively. Revascularization pulses could be palpated
through the dressing, and the low proﬁle permitted identiﬁ-
cation of postoperative soft tissue changes such as hema-
tomas. Compressive Ace bandages (3M, St. Paul, Minn)
could be applied without disturbing the original dressing.
However, the beneﬁcial wound healing effects of the
dressing were not noted in the current trial. There are
confounding factors that occurred during the original
2007 report. The 39-month study period may explain
the discrepancy between the current prospective, multi-
institutional randomized trial ﬁndings and the original
nonconcurrent cohort report.7 For instance, it is possible
that in the second half (months 16-39) of the earlier
nonconcurrent study when the practice switched to the sil-
ver alginate dressing, there was increased attention to prac-
tices such as perioperative antibiotics, normothermia, and
use of skip incisions that might have led to the better results
compared with the period (months 1-15) when conven-
tional sterile cotton gauze was.
The current trial generated almost 64,000 individual
data points that give some insights into risk factors for lower
extremity vascular wound complications. Like others, we
found that a high BMI is associated with increased
risk.10,16,17 However, contrary to two of these prior re-
ports16,17 and others,3 gender was not associated with
wound complication rates. Similar to the Project of Ex-
Vivo Vein Graft Engineering Via Transfection (PREVENT)
III data set,18 Coumadin was linked with increased wound
complications.3 Coumadin use may be a marker for a medi-
cally complex patient prone to wound problems, anticoagu-
lation may generate hematomas and collections prone to
infection, or there may of course be undeﬁned biologic
mechanisms underlying the association of this drug towound complications. Operative time, incision length,
autogenous conduit, and groin combined with leg incisions
were all positively associated with postoperative wound
problems, and these may in part be markers for more exten-
sive vascular surgical procedures. Conversely, the protective
effect in multivariate analyses for no conduit/material prob-
ably relates to this being a marker for a more straightforward
vascular reconstruction.
Limitations are acknowledged. Wound complications
were essentially self-reported by the primary surgical team,
and the study lacked the resources for an independent
follow-up observer. To bolster the overall data set quality,
local National Surgical Quality Improvement Program data
were used (after appropriate approvals) at the two academic
medical centers to verify the primary trial data. The observed
wound complication rates also support a high rate of event
capture. Owing to a protocol design oversight, we did not
collect smoking status on enrollees. In addition, although
the patients and providers were not formally blinded to
the type of original postoperative dressing, the study physi-
cians generally reported an inability to recall which dressing
the patient had received at the late follow-up visits.
We do not have culture data for patients who devel-
oped a SSI. Finally, we also did not tightly regulate the
manner in which the dressing was secured against the inci-
sion or track the subsequent early incisional care.
Despite these limitations the ﬁndings provide insights
into wound complication rates in the endovascular era
(leaving the most complicated cases for open approaches)
and in an increasingly aging population with a rising BMI
and incidence of diabetes. The negative results under the
condition of this trial raise questions into our concepts of
wound complications in these patients. It is possible that
bacterial invasion of these wounds initiates well before
the dressings are applied. Also, the etiology of these wound
complications may fundamentally relate to local ischemia
rather than to a purely infectious primary origin.
CONCLUSIONS
The incidence of wound complications remains high in
contemporary open arterial surgery in the lower extremity.
Under the study conditions, a silver-eluting alginate dressing
showed no effect on wound complication incidence. Recog-
nition of perioperative risk factors may allow for closer sur-
veillance and possible mitigation of wound problems.
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Dr Karen Ho, Dr Marcus Semel, and Dr Edward A. McGil-
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at www.jvascsurg.org.DISCUSSIONDr Jon Matsumura (Madison, Wisc). What other process
measures were in place to address wound complications during
the study? Methicillin-resistant Staphylococcus aureus screening,
normothermia, antibiotic selection and timing?
Dr C. Keith Ozaki. Over the last decade, we have had many
changes and redesign of our care processes to address these issues.
More attention to normothermia, more attention to timely periop-
erative antibiotics, increased considerations of approaches, such as
skip incisions, all of those continued to be implemented over time
and may account for some of the differences between the current
report and the prior nonconcurrent study that had the original
control group ﬁrst and then at a later date had the silver alginate
dressing cohort.
There were a variety of wound practices at these three
different institutions, so I cannot summarize those in just a few
statements. But we did try to design this trial to be applicable to
several different settings, both the civilian and the Veterans Admin-
istration population.Dr Peter Lawrence (Los Angeles, Calif). Did you classify
wounds by degree of contamination? Clean contaminated wounds
in patients with foot infections might beneﬁt from this dressing,
while the average clean wound would not. Did you calculate the
cost/beneﬁt for each group?
Dr Ozaki. That is an excellent point. The cost data related to
this, especially the cost of having a wound complication, will be pre-
sented at Eastern Vascular and New England meetings this fall.
These dressings are actually quite inexpensive. For a 4-by-5 inch
piece, the actual General Services Administration price, and that
translates pretty well to the civilian price, is less than $10.00. We
tested an approach that we thought might be cost-effective even if
there was a very small clinical beneﬁt. Whenever we broke the cases
down into those that were nonclean, we actually by c2 analysis did
see a statistically signiﬁcant beneﬁt for the silver dressing. I did not
present those data though because I do not trust the data. Half of
those caseswere labeled as clean-contaminated.Andby the technical
deﬁnition, that means you either enter a hollow viscus or you have a
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quality of that information.
But you are correct, from our data set we should be able to
select patients most at risk, and maybe for that select population
there could be a role for this type of dressing.
Dr David Yu (Seattle, Wash). I was wondering if the immu-
nocompetence status of these patients were taken into consider-
ation for the study?
Dr Ozaki. I do not have any speciﬁc assays of immune status.
We did have a subset of the patients that were on immunosuppres-
sive prednisone, and there was no differential in the wound compli-
cation rates for these patients.
Dr Jens Eldrup-Jorgensen (Portland, Me). Surgical site in-
fections in our institution have received a lot of scrutiny of late.
I think a lot of the value of this study is to give us a contemporary
assessment of what realistic surgical site infection rates are. We ﬁnd
that in our institution they are very similar to what you are report-
ing here, and yet the expectation is that they should be much
lower, at least from some parties.
We have also tried using a silver-based dressing on a more
empiric approach. And now with the failure of this to show any ef-
ﬁcacy, are you trialing the negative-pressure dressings in some of
these more complex wounds?
Dr Ozaki. Based on some of the earlier reports, I am
intrigued by the negative-pressure dressings even for the closed in-
cisions. That technique warrants further investigation. Actual
infection rates are in the midteens for our lower extremity revascu-
larizations and 6.6% when you have to cut down to do an endovas-
cular aneurysm repair. I think that is useful data, and I think it is
real. All our study institutions had these rates.Dr Cassius Iyad Ochoa Chaar (New Haven, Conn). I
congratulate you on doing a study that is sponsored by industry
but still have data independently analyzed with the investiga-
tors. What were the lengths of those incisions, and were the
anatomical locations comparable in both groups? And for the
groin speciﬁcally, were you able to compare vertical and trans-
verse incisions?
Dr Ozaki. The average incision length was just over 32 cm.
There was not a difference between the groups in incision
length. Regarding the orientation of the groin incision, there
were many confounding factors, such as whether this was a
redo surgery that had a prior vertical incision, whether this
was an obese patient, etc. Most of the endovascular aneurysm
repair participants had a transverse groin incision vs those
with extensive occlusive disease that needed a long profundo-
plasty might have had vertical. So I am nervous about analyzing
that data under these study conditions because of those con-
founding factors. However we do have a lot of granularity in
the data set with regards to location of incisions, types of inci-
sions, and there will be future analyses of those issues.
Dr Palma Shaw (Syracuse, NY). Given the number of
different silver dressings, with different amounts of silver in each
dressing, do you think that there is a role for looking at different
amounts of silver and seeing if this has an effect?
Dr Ozaki. Yes, that is a great point. There are a variety of sil-
ver dressing products. If you talk to another silver dressing manu-
facturer, they will suggest that the reason your study was negative
is because you used the wrong dressing. If there are any industry
partners out there thirsty to really look at this, we are anxious to
have something that will help these patients.
APPENDIX I (online only). Wound grades (at least at postoperative weeks 2 and 4)
/No wound complication
/Superﬁcial incisional SSI: Infection that occurs #30 days after the operation and infection involves only skin/subcutaneous tissue
of the incision and at least one of the following:
d Purulent drainage, with or without laboratory conﬁrmation
d Organisms isolated from an aseptically obtained culture of ﬂuid or tissue from the superﬁcial incision
d At least one of the following signs/symptoms of infection: pain or tenderness, localized swelling, redness, or heat and superﬁcial
incision is deliberately opened by the surgeon, unless incision is culture-negative
d Diagnosis of superﬁcial incisional SSI by surgeon/attending
Do not report stitch abscess (minimal inﬂammation and discharge conﬁned to the points of suture penetration) as SSI.
/Deep incisional SSI: Infection that occurs #30 days after operation and infection appears to be related to the operation and infection
involved deep tissues (fascial/muscle layers) of the incision and at least one of the following:
d Purulent drainage from the deep incision
d A deep incision spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of the following signs
or symptoms: fever (>38C), localized pain, or tenderness, unless site is culture-negative.
d An abscess or other evidence of infection involving the deep incision is found on direct examination, during reoperation, or by
histopathologic or radiologic examination
d Diagnosis of deep incision SSI by surgeon/attending
/Dehiscence: Skin separation requiring local wound care without SSI criteria
/Other: Seroma, lymphocele, hematoma, etc
SSI, Surgical site infection.
APPENDIX II (online only). Data collected (record reviews, phone calls, clinic visit as needed):
d Patient age, gender
d Selected medical history (IDDM, NIDDM; no medications or surgical history)
d Clinical indication for revascularization (claudication, rest pain, tissue loss)
d Most recent selected laboratory results (WBC, hematocrit, platelets, creatinine, blood glucose, albumin)
d Operation date
d Primary attending surgeon
d Revascularization procedure: record all, including laterality (nonfemoral inﬂow to femoral, fem-fem, groin reconstruction only,
fem-AK popliteal, fem-BK popliteal, fem tibial/pedal, popliteal-tibial, tibial-tibial) and conduit (autogenous, prosthetic, composite
prosthetic/composite, homograft)
d Sterile preparation solution
d Case length (incision to dressing in minutes)
d Perioperative antibiotics and time from incision, intraoperative doses
d PACU/ICU ﬁrst postoperative temperature
d EBL
d Postoperative therapeutic anticoagulation
d Anesthetic approach (regional vs general)
d Intraoperative transfusions (units of PRBC, FFP, platelets)
d Surgical wound classiﬁcation (clean, clean-contaminated, contaminated, dirty/infected)
d Wound complications, classiﬁed generally according to NSQIP8 #30 days, either leg
d EQ-5D at consent/baseline, 2 weeks, and 4 weeks
d Primary, primary assisted, and secondary patency rates at 30 days and 1 year via life table
d Limb loss with 1 year by life-table analysis
d Readmission for wound complications, LOS
d Death #30 days
d Measured post operative incision length, as a proxy for quantity of dressing utilized
d Index LOS
d Days of antibiotic administration
d Days of active incisional wound care during and after discharge (including at home and at rehabilitation facilities)
B Type and frequency of wound care
d Readmission LOS for wound care and cumulative LOS for the duration of the study period
d Additional operative procedures required for incisional wound care during index LOS and readmission LOS
AK, Above knee; BK, below knee; EBL, estimated blood loss; FFP, fresh frozen plasma; ICU, intensive care unit; IDDM, Insulin-dependent diabetes mellitus;
LOS, length of stay; NIDDM, non-insulin-dependent diabetes mellitus; NSQIP, National Surgical Quality Improvement Program; PACU, postanesthesia care
unit; PRBC, packed red blood cells; WBC, white blood cell.
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